Newsroom
All News
- All News
- In the News
- Press Releases
- Publications
- Events
- Video
- Noteworthy Articles
Most People Don’t Know What Sepsis Is
September is Sepsis Awareness Month and part of the problem in fighting sepsis is that most people don’t know what it is, reports Westwood One. However, now there may be a faster way to detect it. Sepsis occurs when the body’s efforts to fight an infection trigger inflammation throughout the...
European and U.S. Patent Allowances Strengthen Immunexpress’ Leading Position in Host-Response Sepsis Diagnostics
Patent Allowances Relate to SeptiCyte™ Technology Using Biomarkers These allowances further reinforce the claims of the core family of patents that support the Company’s gene expression technology in the detection of host response to sepsis SEATTLE, Sept. 24, 2018 – Immunexpress, Inc., today announced the receipt of ‘Notices of Allowance’...
Avoidable Sepsis Infections Send Thousands Of Seniors To Gruesome Deaths
No one tracks sepsis cases closely enough to know how often these severe infections turn fatal. But the toll — both human and financial — is enormous, finds an investigation by KHN and the Chicago Tribune. By Fred Schulte and Elizabeth Lucas and Joe Mahr, Chicago Tribune.
Immunexpress Saving Lives with Improved Sepsis Diagnosis: Interview with Rolland Carlson PhD, CEO
Medgadget editor Tom Peach sat down with Dr.Carlson from Immunexpress to hear more about the company’s first FDA-approved sepsis diagnostic test, SeptiCyte, and what the future of sepsis diagnosis and treatment may look like.
Immunexpress is proud to be one of the sponsors for the 2nd World Sepsis Conference, Sept 5-6, 2018
"The 2nd World Sepsis Congress will be held on September 5th and 6th, 2018 - free of charge and completely online, so you can participate from wherever you have an internet connection. Over the course of 17 sessions, more than 100 speakers from 30 countries will discuss all aspects of...
3 Need-to-Know Leaps in Sepsis Care
Rolland Carlson, PhD, CEO of Immunexpress, discusses a different approach to the sepsis battle. Rather than passively chasing pathogens, the Company has developed a test to measure the body's specific immune response to infection by examining biomarkers in the patient's blood.
Immunexpress is a finalist for the 2018 MedTech Best Proof-of-Value of an Innovation award
"LONDON – AUGUST 13, 2018 – Informa Pharma Intelligence today announces the finalists for the 2018 Medtech Insight Awards. The diverse group of finalists were chosen by a highly respected independent panel of experts from across the sector." -- Pharma Intelligence https://pharmaintelligence.informa.com/events/awards/medtech-insight-awards-2018
Immunexpress Receives Notice of U.S. Patent Allowance for SeptiCyte™ Technology to Quantify Biomarkers
The allowance complements the Company's growing patent portfolio of gene technology in the detection of host response to sepsis SEATTLE, July 26, 2018 /PRNewswire/ -- Immunexpress, Inc. today announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for U.S. Patent Application No. 15/160749, "Validating biomarker...
Appointments and advancements – Fayyaz Memon
Immunexpress continues executive team expansion with addition of Fayyaz Memon as VP of Regulatory Affairs & Quality.
Immunexpress Continues Executive Team Expansion with Addition of Fayyaz Memon as VP of Regulatory Affairs & Quality
SEATTLE, July 10, 2018 /PRNewswire/ -- Immunexpress, Inc. today announced that Fayyaz Memon, MBA, MS, has joined the company's Executive Team as Vice President of Regulatory Affairs and Quality. "Mr. Memon arrives at a key time for the Company as we continue to fortify our leadership team with accomplished individuals well-versed in the life sciences...
If you are a member of the media, please contact:
Maggie Beller
Russo Partners
(646) 942-5631
maggie.beller@russopartnersllc.com